1.Pharmacotherapy of Poststroke Aphasia
International Journal of Cerebrovascular Diseases 2008;16(12):917-920
Stroke is the most common cause of aphasia. Traditional speech-language therapy remains the mainstay treatment of aphasia, however, its efficacy is uncertain. Although a number of studies have been carried out to investigate the role of pharmacological agents in the treatment of aphasia, the conclusions are controversial, This article reviews the state of pharma-colotherapy for poststroke aphasia.
2.Efficacy of irbesartan combined with metoprolol in the treatment of patients with chronic congestive heart failure
Chinese Journal of Primary Medicine and Pharmacy 2017;24(17):2639-2643
Objective To observe the efficacy of irbesartan combined with metoprolol in the treatment of chronic congestive heart failure.Methods From April 2015 to April 2016,60 patients with chronic congestive heart failure in Central Hospital of Zhuji were randomly divided into the observation group and the control group,30 cases in each group.The two groups were given conventional treatment,the control group was treated with metoprolol,and the observation group was treated with irbesartan combined with metoprolol.The changes of left ventricular ejection fraction (LVEF),left ventricular end systolic diameter (LVESD),left ventricular end diastolic diameter (LVEDD),heart rate,systolic pressure and diastolic pressure before and after treatment in two groups were observed.And the clinical efficacy of the two groups was compared.Results After treatment,compared with the control group,the heart function index of the observation group changed obviously,LVEF increased (t=5.88,P<0.01),LVESD and LVEDD significantly decreased (t=7.19,4.11,all P<0.01).The heart rate of the observation group was significantly slowed down (t=2.72,P<0.01),systolic blood pressure and diastolic blood pressure were also significantly reduced (t=2.93,3.98,all P<0.01).The total effective rate of the observation group was 93.3%,which of the control group was 73.3%,the difference was statistically significant (χ2=4.32,P<0.05).ConclusionIrbesartan combined with metoprolol in the treatment of chronic congestive heart failure has significant clinical efficacy,is conducive to ease the clinical symptoms and improve heart function effectively.
3.Analysis of Drug Utilization in Herpes Zoster Patients from 22 Hospitals of Shanghai Area during 2013-2015
China Pharmacy 2017;28(8):1037-1040
OBJECTIVE:To investigate the utilization and trend of drugs for herpes zoster patients from 22 hospitals of Shanghai area,and to provide reference for rational use of drugs.METHODS:The utilization of drugs for herpes zoster patients from 22 hospitals of Shanghai area during 2013-2015 was analyzed statistically in respects of proportion of patients,consumption sum,DDDs,DDC,etc.RESULTS:Herpes zoster was more likely to occur in adults,mostly in more than 45 year-old group (>75%).The proportions of patients of neurotrophic antivirals,anti-herpes virus and acesodyne drugs ranked in the top three.Topical,immu nomodulatory and glucocorticoid drugs accounted for a certain proportion.Among antivirals,the consumption sum and DDDs of valaciclovir ranked the first place,and DDC of brivudine was the highest.Among acesodyne,the proportions of patients of antiepileptic drugs was the highest (13.78%),and its compound growth rate was also the highest (30.77%);the number of patients of gabapentin was the largest.Among neurotrophic drags,the proportions of patients of mecobalamine was the highest (32.98%).Among immunomodulatory drugs,the number of patients of thymalfasin was the largest,which may be irrational.CONCLUSIONS:The treatment of herpes zoster in Shanghai area is basically in accordance with the guidelines.The irrational use of immunomodulatory drugs should be paid attention to and supervised.
4.Analysis of Non-irrational Drug Use in the Department of Cardiovascular Diseases
China Pharmacy 1991;0(05):-
OBJECTIVE: To evaluate the irrational use of drugs in the department of cardiovascular diseases.METHODS: The irrational use of drugs in the department of cardiovascular diseases from Nov,2007 to Aug 2008 was analyzed statistically.RESULTS: Of the total 194 inpatients(1 745 times in total) investigated,irrational use of antibiotics were found in 118 cases,accounting for 60.82% of the total inpatients or 6.76% in the total 1 745 times;26 cases involved irrational perioperative use of antibiotics,accounting for 1.49% of the total 1 745 times;76 cases had irrational use of non-antibiotics,accounting for 39.18% of the total inpatients or 4.36% of the total 1 745 times.The irrational drug use in the cardiovascular department witnessed an improvement ever since Feb 2008 when the full-time clinical pharmacists began their work in this department.CONCLUSION: The clinical pharmacists can enhance the clinical rational drug use level by summarizing experience and carrying out pharmaceutical care accordingly.
5.Antalgic Value of Infiltrating Anesthesia of Uterine Cavity in the Interventional Treatment of Uterine Aterial Embolization
Journal of Practical Radiology 2001;0(08):-
Objective To explore the antalgic value of infiltrating anesthesia of intra-uterine cavity in the interventional therapy of uterine arterial embolization.Methods 69 patients with hysteromyoma were divided into group A(25 cases),B(21 cases) and C(23 cases),then transcatheter superselective uterine arterial angiography and embolization were performed with intramuscular injection of Pethidine,administration of Dexamethasone with Ibuprofen through uterine artery and infiltrating anesthesia of uterine cavity respectively in group A,B and C.The antalgic effect after embolization was evaluated.Results The antalgic excellent rates were 29%,52% and 84% respectively in group A,B and C.Conclusion The antalgic efficiency with infiltrating anesthesia of uterine cavity is well, it is worthy to be used in the treatment of uterine aterial embolization in clinic.
6.Clinical study of ursodeoxycholic acid combined with reduced glutathione for non-alcoholic fatty liver disease
Chinese Journal of Primary Medicine and Pharmacy 2017;24(11):1650-1653
Objective To explore the clinical curative effect of ursodeoxycholic acid combined with reduced glutathione for non-alcoholic fatty liver disease.Methods 128 patients with non-alcoholic fatty liver disease in our hospital were selected, and they were randomly divided into control group and research group,64 cases in each group.The control group received ursodeoxycholic acid capsules, the research group received reduced glutathione tablet on the basis of ursodeoxycholic acid capsules,the two groups received treatment of two periods, each period had one and half months.The liver function and blood lipid were detected and compared between the two groups.Results The total clinical effective rate of the research group was 93.75%, which of the control group was 68.75% (x2=20.5,P=0.000),the difference was statistically significant.After treatment, liver function (ALT, AST, TBIL, GGT and ALP) and lipid levels (TG and CHO) of the two groups were improved significantly[the control group:before treatment (138.75±30.63) IU/L,(161.72±55.61) IU/L,(183.65±58.47) μmol/L,(213.65±40.35) IU/L,(82.38±23.15) IU/L,(2.85±0.77) μmol/L,(6.45±0.37) μmol/L, after treatment (66.38±26.31) IU/L,(65.39±22.15) IU/L,(92.38±36.15) μmol/L,(99.68±36.72) IU/L,(30.23±10.36) IU/L,(1.92±0.58) mol/L,(5.39±0.53) μmol/L;the research group before treatment (141.25±32.53) IU/L,(157.56±58.31) IU/L,(190.23±51.27) μmol/L,(223.72±43.18) IU/L,(80.86±21.85) IU/L,(2.92±0.73) μmol/L,(6.43±0.82) μmol/L, after treatment (37.64±11.25) IU/L,(36.25±11.83) IU/L,(47.67±8.32) μmol/L,(70.52±26.31) IU/L,(16.69±7.32) IU/L,(1.32±0.63) μmol/L,(4.31±0.63) μmol/L],the differences were statistically significant(the control group :t=14.3,12.9,10.6,16.7,16.4,7.7,13.1,all P<0.01;the research group:t=24.1,25.4,21.9,24.2,16.1,13.3,16.4,all P<0.01),but these indicators of the research group were improved significantly better than those of the control group, the differences were statistically significant(t=8.0,9.3,9.6,8.5,8.5,5.6,10.5;all P<0.01).Conclusion The clinical curative effect of research group is distinct, safe and has no obvious adverse reactions, which is worthy of clinical application.
7.Research Progress of Acupuncture-moxibustion in Treating Toothache
Shanghai Journal of Acupuncture and Moxibustion 2015;(5):483-486
Objective To discuss the clinical efficacy and mechanism research progress of acupuncture-moxibustion in treating toothache, for providing better treatment methods and clinical evidence.Method Taking “toothache”, “acupuncture”, “moxibustion”, “acupoint” as the key terms, clinical research literatures about acupuncture-moxibustion in treating toothache during the recent 10 years were retrieved by using computer, and were then arranged and analyzed.Result There is a variety of acupuncture-moxibustion methods in treating toothache, and the methods are effective.Conclusion Acupuncture-moxibustion therapy is effective in treating toothache, and deserves a large-sample multi-centered randomized research.
8.Determination of Tanshinone Ⅱ_A and Schizandrol A in Anshenbuxin Pill by HPLC
Chinese Traditional Patent Medicine 1992;0(07):-
AIM: To develop a method to determine the content of Tanshinone Ⅱ A and Schizandrol A in Anshenbuxin Pill(Radix Salviae Miltiorrhizae, Fructus Schisandrae Chinensis, Rhizoma Acori Tatarinowii,etc.). METHODS: HPLC was used to determine the content of Tanshinone Ⅱ A and Schizandrol A in Anshenbuxin Pill. The separation was performed on C 18 column with methanol water (80∶20) for Tanshinone Ⅱ A and methanol water(50∶50) for Schizandrol A, respectively. The detection wavelength was at 270nm for Tanshinone Ⅱ A and 250nm for Schizandrol A, respectively. RESULTS: The average recovery of Tanshinone Ⅱ A was 98.54%( RSD =1.75%, n =6) and the average recovery of Schizandrol A was 99.05%( RSD =1.77%, n =6). CONCLUSION: This method is simple, accurate with good reproducibility and can be used to control the quality of Anshenbuxin Pill.
9.Effects of gender on post-stroke aphasia
Journal of Shanghai Jiaotong University(Medical Science) 2006;0(08):-
70 years old)(P